Seizing The Day: How Coronavirus Breaks Then Makes Vaccine Makers In China
Executive Summary
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
You may also be interested in...
When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day
While global vaccine heavyweights such as Merck & Co, Sanofi and GSK have somewhat lagged in the development of vaccines for COVID-19, smaller players have stepped up. This is especially true for highly segmented markets such as China, where agility has been important.
Webinar Recording: Coronavirus Pharma Industry Impact In China, Korea And Japan
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.